Fig. 1From: Impact of frontline treatment approach on outcomes of myeloid blast phase CMLCumulative incidence of relapse (CIR) based on a therapeutic approach including (a) any TKI or (b and c) only including regimens with a 2nd/3rd-generation TKI. p-values are between the indicated group and the TKI monotherapy groupBack to article page